NCT04079712 2026-04-13
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT04471727 2026-02-24
MK-6070-001
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2 Active not recruiting
NCT03600233 2025-12-23
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
TaiRx, Inc.
Phase 2 Active not recruiting
NCT03728361 2025-12-18
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05064150 2025-12-18
NET-PRO
University of Iowa
Active not recruiting
NCT05262556 2025-08-07
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT02754297 2024-08-21
P-PRRT
CHU de Quebec-Universite Laval
Phase 2 Active not recruiting
NCT04524208 2024-08-13
CABONEN
University Medical Center Goettingen
Phase 2 Active not recruiting